Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | phosphodiesterase 3A, cGMP-inhibited | Starlite/ChEMBL | References |
Homo sapiens | phosphodiesterase 4A, cAMP-specific | Starlite/ChEMBL | References |
Homo sapiens | phosphodiesterase 4D, cAMP-specific | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | metabotropic GABA-B receptor subtype 2 | 0.0358 | 0.0819 | 0.0819 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.1398 | 0.7823 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.1171 | 0.6295 | 0.6906 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0681 | 0.2995 | 0.3286 |
Brugia malayi | 3'5'-cyclic nucleotide phosphodiesterase family protein | 0.0541 | 0.2048 | 0.1755 |
Toxoplasma gondii | 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein | 0.0237 | 0 | 0.5 |
Loa Loa (eye worm) | glutamate receptor | 0.055 | 0.211 | 0.211 |
Loa Loa (eye worm) | hypothetical protein | 0.1721 | 1 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.1589 | 0.9114 | 1 |
Echinococcus multilocularis | metabotropic glutamate receptor 2 | 0.1171 | 0.6295 | 0.6295 |
Giardia lamblia | CAMP-specific 3,5-cyclic phosphodiesterase 4B | 0.0237 | 0 | 0.5 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.1721 | 1 | 1 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.1266 | 0.6938 | 0.8736 |
Loa Loa (eye worm) | glutamate receptor | 0.1398 | 0.7823 | 0.7823 |
Loa Loa (eye worm) | hypothetical protein | 0.0541 | 0.2048 | 0.2048 |
Brugia malayi | metabotropic glutamate receptor type 2 | 0.0681 | 0.2995 | 0.3107 |
Echinococcus granulosus | metabotropic glutamate receptor 2 | 0.1171 | 0.6295 | 0.6295 |
Loa Loa (eye worm) | hypothetical protein | 0.05 | 0.1773 | 0.1773 |
Loa Loa (eye worm) | receptor family ligand binding region containing protein | 0.0358 | 0.0819 | 0.0819 |
Loa Loa (eye worm) | hypothetical protein | 0.0358 | 0.0819 | 0.0819 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 7.8 uM | Evaluated for its ability to inhibit PDE3. | ChEMBL. | 9873643 |
IC50 (binding) | = 7.8 uM | Evaluated for its ability to inhibit PDE3. | ChEMBL. | 9873643 |
IC50 (binding) | = 8.5 uM | Evaluated for its ability to inhibit PDE4D. | ChEMBL. | 9873643 |
IC50 (binding) | = 8.5 uM | Evaluated for its ability to inhibit PDE4D. | ChEMBL. | 9873643 |
IC50 (binding) | = 14 uM | Evaluated for its ability to inhibit PDE4A. | ChEMBL. | 9873643 |
IC50 (binding) | = 14 uM | Evaluated for its ability to inhibit PDE4A. | ChEMBL. | 9873643 |
IC50 (binding) | = 22 uM | Evaluated for its ability to inhibit PDE4B. | ChEMBL. | 9873643 |
IC50 (binding) | = 22 uM | Evaluated for its ability to inhibit PDE4B. | ChEMBL. | 9873643 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.